FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005024095> ?p ?o ?g. }

• W2005024095 endingPage "871" @default.
• W2005024095 startingPage "865" @default.
• W2005024095 abstract "<h3>Objective:</h3> To find biomarkers identifying patients at risk for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment. <h3>Methods:</h3> Patients were recruited from 10 European and US cohorts. Of 289 patients with multiple sclerosis (MS), 224 had been treated with natalizumab (18–80 months), 21 received other immune-modulatory treatments, and 28 were untreated. We had access to samples from 16 natalizumab PML patients. Eight of these patients had given blood before the diagnosis of PML. We also analyzed non-natalizumab-treated patients who developed PML (n = 10) and age- and sex-matched healthy donors (n = 31). All flow cytometric assessments were done on previously cryopreserved, viable peripheral blood mononuclear cells. <h3>Results:</h3> The percentage of l-selectin-expressing CD4+ T cells was significantly lower in patients treated long-term with natalizumab (40.2%) when compared with patients not receiving natalizumab treatment (47.2%; <i>p</i> = 0.016) or healthy controls (61.0%; <i>p</i> < 0.0001). An unusually low percentage (9-fold lower; 4.6%) was highly correlated with the risk of developing PML in the patient group with available pre-PML samples when compared with non-PML natalizumab-treated patients (<i>p</i> ≤ 0.0001). Samples were gathered between 4 and 26 months before PML diagnosis. <h3>Conclusions:</h3> The cell-based assessment of the percentage of l-selectin-expressing CD4 T cells could provide an urgently needed biomarker for individual PML risk assessment." @default.
• W2005024095 created "2016-06-24" @default.
• W2005024095 creator A5003159414 @default.
• W2005024095 creator A5005103364 @default.
• W2005024095 creator A5009943200 @default.
• W2005024095 creator A5011686938 @default.
• W2005024095 creator A5015607908 @default.
• W2005024095 creator A5020671355 @default.
• W2005024095 creator A5021067270 @default.
• W2005024095 creator A5025462803 @default.
• W2005024095 creator A5026430936 @default.
• W2005024095 creator A5027116773 @default.
• W2005024095 creator A5029382535 @default.
• W2005024095 creator A5031075667 @default.
• W2005024095 creator A5034872348 @default.
• W2005024095 creator A5035288524 @default.
• W2005024095 creator A5038373894 @default.
• W2005024095 creator A5038394370 @default.
• W2005024095 creator A5052848358 @default.
• W2005024095 creator A5054895816 @default.
• W2005024095 creator A5056003125 @default.
• W2005024095 creator A5056910421 @default.
• W2005024095 creator A5057464377 @default.
• W2005024095 creator A5057598570 @default.
• W2005024095 creator A5061856360 @default.
• W2005024095 creator A5062220148 @default.
• W2005024095 creator A5062485514 @default.
• W2005024095 creator A5075919533 @default.
• W2005024095 creator A5077055545 @default.
• W2005024095 creator A5081181403 @default.
• W2005024095 creator A5081885557 @default.
• W2005024095 creator A5089682223 @default.
• W2005024095 date "2013-08-07" @default.
• W2005024095 modified "2023-10-12" @default.
• W2005024095 title "L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients" @default.
• W2005024095 cites W1974438776 @default.
• W2005024095 cites W1978358359 @default.
• W2005024095 cites W1986355431 @default.
• W2005024095 cites W1986720623 @default.
• W2005024095 cites W1994381563 @default.
• W2005024095 cites W1995385281 @default.
• W2005024095 cites W2011257051 @default.
• W2005024095 cites W2012174890 @default.
• W2005024095 cites W2027732093 @default.
• W2005024095 cites W2044022462 @default.
• W2005024095 cites W2057903396 @default.
• W2005024095 cites W2061887343 @default.
• W2005024095 cites W2062606699 @default.
• W2005024095 cites W2065150630 @default.
• W2005024095 cites W2076230401 @default.
• W2005024095 cites W2077783001 @default.
• W2005024095 cites W2085771265 @default.
• W2005024095 cites W2103758700 @default.
• W2005024095 cites W2106049687 @default.
• W2005024095 cites W2106747769 @default.
• W2005024095 cites W2110166193 @default.
• W2005024095 cites W2111856386 @default.
• W2005024095 cites W2129327924 @default.
• W2005024095 cites W2130496327 @default.
• W2005024095 cites W2130970970 @default.
• W2005024095 cites W2145774108 @default.
• W2005024095 cites W2155620154 @default.
• W2005024095 cites W2155631416 @default.
• W2005024095 cites W2172275967 @default.
• W2005024095 cites W2916040650 @default.
• W2005024095 doi "https://doi.org/10.1212/wnl.0b013e3182a351fb" @default.
• W2005024095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23925765" @default.
• W2005024095 hasPublicationYear "2013" @default.
• W2005024095 type Work @default.
• W2005024095 sameAs 2005024095 @default.
• W2005024095 citedByCount "134" @default.
• W2005024095 countsByYear W20050240952013 @default.
• W2005024095 countsByYear W20050240952014 @default.
• W2005024095 countsByYear W20050240952015 @default.
• W2005024095 countsByYear W20050240952016 @default.
• W2005024095 countsByYear W20050240952017 @default.
• W2005024095 countsByYear W20050240952018 @default.
• W2005024095 countsByYear W20050240952019 @default.
• W2005024095 countsByYear W20050240952020 @default.
• W2005024095 countsByYear W20050240952021 @default.
• W2005024095 countsByYear W20050240952022 @default.
• W2005024095 crossrefType "journal-article" @default.
• W2005024095 hasAuthorship W2005024095A5003159414 @default.
• W2005024095 hasAuthorship W2005024095A5005103364 @default.
• W2005024095 hasAuthorship W2005024095A5009943200 @default.
• W2005024095 hasAuthorship W2005024095A5011686938 @default.
• W2005024095 hasAuthorship W2005024095A5015607908 @default.
• W2005024095 hasAuthorship W2005024095A5020671355 @default.
• W2005024095 hasAuthorship W2005024095A5021067270 @default.
• W2005024095 hasAuthorship W2005024095A5025462803 @default.
• W2005024095 hasAuthorship W2005024095A5026430936 @default.
• W2005024095 hasAuthorship W2005024095A5027116773 @default.
• W2005024095 hasAuthorship W2005024095A5029382535 @default.
• W2005024095 hasAuthorship W2005024095A5031075667 @default.
• W2005024095 hasAuthorship W2005024095A5034872348 @default.
• W2005024095 hasAuthorship W2005024095A5035288524 @default.
• W2005024095 hasAuthorship W2005024095A5038373894 @default.
• W2005024095 hasAuthorship W2005024095A5038394370 @default.

• next